Fundraising FoxLiminatus Pharma
NASDAQ: LIMNFullerton, US · Delaware corporation
Find your way into Liminatus Pharma
Sign up to see every warm intro you have to Liminatus Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Liminatus Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Liminatus Pharma is a biotechnology company developing cancer immunotherapies, including a CD47 blockade program and multiple CAR-T cell therapy candidates. Its pipeline targets various tumor-associated antigens for oncology treatment.
Founders & leadership
BC
Byong C. YooExecutive
SD
Sang-jin Daniel LeeExecutive
SD
Scott DamExecutive
BK
Beom K. ChoiExecutive
Board
ES
Eun Sook LeeBoard director
NF
Nicholas FernandezBoard director
JY
Ji Yeon BaekBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 1 of 2 rounds · 2025–2026
▶$1.9MraisedJun 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.9MraisedJun 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
- Nicholas FernandezDirector
- Ji Yeon BaekDirector
- Byong C. YooExecutive Officer
- Chris KimExecutive Officer, Director
- Eun Sook LeeDirector
- Sang-jin Daniel LeeExecutive Officer
- Scott DamExecutive Officer
- Beom K. ChoiExecutive Officer
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- Sales commissions
- $149K
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$9Mvaluation at IPOFeb 2026 · $0.29/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Liminatus Pharma do?
- Liminatus Pharma is a biotechnology company developing cancer immunotherapies, including a CD47 blockade program and multiple CAR-T cell therapy candidates. Its pipeline targets various tumor-associated antigens for oncology treatment.
- How much funding has Liminatus Pharma raised?
- Liminatus Pharma has disclosed $1.9M raised across 1 of its 2 known rounds.
- Where is Liminatus Pharma headquartered?
- Liminatus Pharma is headquartered in Fullerton, US.